精准医疗市场规模、份额和成长分析：按类型、适应症、最终用途和地区划分 - 产业预测，2024-2031 年

2022年全球精准医疗市场规模将达285亿美元，预测期间（2024-2031年）复合年增长率为11.4%，从2023年的317.5亿美元成长到2031年的753亿美元。

基因组研究、生物技术和资料分析的进步预计将推动精准医疗市场的显着成长。癌症和心血管疾病等慢性疾病的盛行率不断上升，推动了对精准医疗提供的个人化治疗计划的需求。这种方法是基于这样的想法：即使是同一种疾病，也会根据遗传和环境因素对治疗产生不同的反应。根据SkyQuest分析，2023年全球精准医疗治疗支出达380.9亿美元。精准医学会考虑患者的症状、遗传讯息和环境影响来调整治疗策略。系统生物学和泛组学经常参与研究患者症状的分子原因并开发标靶治疗。精准医疗的好处包括根据个人需求和疾病类型量身定制更有效的治疗方法，有可能降低治疗成本并最大限度地减少不必要的药物干预。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 技术分析
• 价格分析
• 价值链分析
• 供应链分析
• 管道分析
• 专利分析
• 贸易分析
• 客户和购买标准分析
• 市场生态系统
• 监管环境
• 创新矩阵
• 重点投资分析
• 关键成功因素
• 竞争程度

精准医疗市场：依类型

• 市场概况
• 抑制剂
• 单株抗体
• 细胞和基因治疗
• 抗病毒药物/抗逆转录病毒药物
• 其他治疗产品

精准医疗市场：依适应症分类

• 市场概况
• 肿瘤学
• 罕见疾病
• 感染疾病
• 血液疾病
• 其他适应症

精准医疗市场：依最终用户分类

• 市场概况
• 医院/诊所
• 居家医疗

精准医疗市场规模：依地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Illumina, Inc.（US）
• Thermo Fisher Scientific Inc.（US）
• Novartis AG（Switzerland）
• Abbott Laboratories（US）
• Agilent Technologies（US）
• Almac Group（Northern Ireland）
• Amgen Inc.（US）
• Astellas Pharma Inc.（Japan）
• AstraZeneca PLC（United Kingdom）
• Bio-Rad Laboratories, Inc.（US）
• Bristol-Myers Squibb Company（US）
• Danaher Corporation（US）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• GE Healthcare（US）
• Intomics A/S（Denmark）
• Merck & Co., Inc.（US）
• Myriad Genetics, Inc.（US）
• Pfizer Inc.（US）
• Qiagen NV（Germany）
• Quest Diagnostics（US）

Global Precision Medicine Market size was valued at USD 28.50 billion in 2022 and is poised to grow from USD 31.75 billion in 2023 to USD 75.30 billion by 2031, growing at a CAGR of 11.4% in the forecast period (2024-2031).

The precision medicine market is projected to experience significant growth, driven by advances in genomic research, biotechnology, and data analytics. The rising prevalence of chronic diseases, such as cancer and cardiovascular conditions, is fueling demand for personalized treatment plans that precision medicine provides. This approach is based on the concept that individuals with the same disease may respond differently to treatment based on their unique genetic and environmental factors. Based on SkyQuest's analysis, global spending on precision medicine treatments reached USD 38.09 billion in 2023. Precision medicine takes into account a patient's symptoms, genetic information, and environmental influences to tailor treatment strategies. It often involves system biology and pan-omics to investigate the molecular causes of a patient's condition and develop targeted therapies. The benefits of precision medicine include more effective treatments customized to individual needs and disease types, potentially reducing treatment costs and minimizing unnecessary pharmaceutical interventions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Precision Medicine Software market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Precision Medicine Software Market Segmental Analysis

The precision medicine market is segmented based on Type, Indication, End-user, and Region. Based on Type, the market is segmented into Inhibitor Drugs, Monoclonal Antibodies, Cell and Gene Therapy, Antiviral and Antiretroviral Drugs, and Others. Based on Indication, the market is segmented into Oncology, Rare Diseases, Infectious Diseases, Hematological Disorders, and Others. Based on End-user, the market is segmented into Hospitals & Clinics, and Home Care Settings. Based on Region, the market is segmented into North America, Europe, Asia-Pacific, South America, and Middle East and Africa.

Drivers of the Global Precision Medicine Software Market

Advancements in cancer biologics are a key driver behind the growth of precision medicine in the global market. The development of innovative therapeutic approaches, such as gene therapy for cancer treatment, is also expected to further accelerate market expansion. Precision medicine provides customized solutions tailored to patients' genetic profiles and disease characteristics, offering the potential for better outcomes and fewer side effects compared to traditional treatments.

Restraints in the Global Precision Medicine Software Market

Precision medicine is advancing rapidly, but the rising costs of diagnostics could hinder market growth. The process of diagnosing and treating patients generates a substantial amount of personal data, and associated privacy risks may restrict the market's expansion. Additionally, stringent regulations and standards are posing challenges to the growth of the personalized medicine sector.

Market Trends of the Global Precision Medicine Software Market

A key trend in the precision medicine market is the integration of advanced computer technologies, such as artificial intelligence (AI) and machine learning, into medication management. These technologies help organize extensive health and genetic data, leading to improved insights into disease patterns and treatment effectiveness. AI identifies new health indicators and develops personalized treatment strategies, enhancing research and care quality. This shift is driving innovative approaches and smart strategies in the adoption of precision medicine.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Pipeline Analysis
• Patent Analysis
• Trade Analysis
• Customer & Buying Criteria Analysis
• Ecosystem of the Market
• Regulatory Landscape
• Innovation Matrix
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Global Precision Medicine Market by Type

• Market Overview
• Inhibitor drugs
• Monoclonal antibodies
• Cell and gene therapy
• Antiviral and antiretroviral drugs
• Other therapeutic products

Global Precision Medicine Market by Indication

• Market Overview
• Oncology
• Rare diseases
• Infectious diseases
• Hematological disorders
• Other indications

Global Precision Medicine Market by End User

• Market Overview
• Hospitals and Clinics
• Home Care Settings

Global Precision Medicine Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Illumina, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almac Group (Northern Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE Healthcare (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intomics A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen N.V. (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Quest Diagnostics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments